Morgan Stanley Remains a Hold on Align Tech (ALGN)


Morgan Stanley analyst Steve Beuchaw maintained a Hold rating on Align Tech (NASDAQ: ALGN) today and set a price target of $320. The company’s shares closed yesterday at $342.87.

According to TipRanks.com, Beuchaw is a 4-star analyst with an average return of 12.7% and a 62.5% success rate. Beuchaw covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA Inc, Myriad Genetics, and Danaher Corp.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Align Tech with a $405.60 average price target.

See today’s analyst top recommended stocks >>

Based on Align Tech’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $106 million. In comparison, last year the company had a net profit of $82.56 million.

Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Align Technology, Inc. engages in the manufacture, design, and marketing of global medical devices. It operates through the Clear Aligner, and Scanner and Services segments. The Clear Aligner segment consists of invisalign full, teen and assist products, and vivera retainers along with training and ancillary products for treating malocclusion.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts